(Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX ® (cabozantinib) versus placebo in patients with previously treated advanced ...

Additional frequent signs can be lumps, unexplained bleeding or ongoing bloating. Nevertheless, one less recognised symptom ...

Phase II trial shows belzutifan effectively shrinks rare neuroendocrine tumors and improves symptoms, offering hope for ...

An analysis of patient records suggests that mRNA covid-19 vaccines boost the immune response to cancerous tumours when given ...

The European Society for Medical Oncology "Living Guideline" for Gastric Cancer suggests that narrow-band imaging or ...

Improvements in survival were seen for those residing in rural and high-poverty communities in Medicaid expansion states.

Medicaid expansion was associated with significantly improved 5-year cancer survival for patients in rural and high-poverty areas compared to non-expansion states. Five-year cause-specific survival ...

While in the fourth year of pursuing her doctorate in immunology at the University of Minnesota, Anderson was diagnosed with ...

Now four years into a first-in-class FDA approval for certain HR-positive, HER2-negative early breast cancers, Eli Lilly’s ...

More than half of children and adolescents diagnosed with thyroid cancer have an excellent response to treatment, but cancer ...

Cancer rates in young people are growing, and those in the GI tract are rising fastest of all. Here are five things to know about colorectal cancer from an expert.